AFP and hepatocellular carcinoma: Data from the current study suggested that as an individual biomarker, PIVKA-II demonstrated the ability to diagnose HCV-HCC accurately; moreover, the diagnostic ability of PIVKA-II was better than that of AFP or AFP‐L3% used alone, with higher AUC (0.859 [0.819-0.893]) values and greater sensitivity (76.8% [69.7-82.9%]) and specificity (87.1% [81.5-91.4%]) than the other two biomarkers.